Market research
4597.TSE Solasia Pharma K.K
TSE JPY Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- P/E ratio
- Not available
- Analyst target
- 120
- Dividend yield
- Not available
- Beta
- 1.18
Profile
Company facts
- Exchange
- TSE
- Currency
- JPY
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- JP3436500007
- P/E ratio
- Not available
- Analyst target
- 120
- Dividend yield
- Not available
- Beta
- 1.18
About
About Solasia Pharma K.K
Solasia Pharma K.K. develops, markets, imports, and exports pharmaceutical products and medical devices in Japan, China, South Korea, and internationally. The company offers Episil (SP-03), an oral liquid for oral mucositis/stomatitis; DARVIAS (SP-02), an antineoplastic agent injection for relapsed or refractory peripheral T-cell lymphoma; and Sancuso (SP-01) for chemotherapy-induced nausea and vomiting. It also develops SP-04, which is in a preclinical trial for chemotherapy-induced peripheral neuropathy; and SP-05, which is in a preclinical trial for colorectal cancer. The company was formerly known as JapanBridge, Inc. and changed its name to Solasia Pharma K.K. in September 2008. Solasia Pharma K.K. was founded in 2006 and is headquartered in Minato, Japan.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 4597.TSE discussion.
5 years, 6 months ago
Solasia Pharma K.K is currently in a long term uptrend where the price is trading 3.8% above its 200 day moving average.
From a valuation standpoint, the stock is 43.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 39.8.
Solasia Pharma K.K's total revenue sank by 83.6% to $167M since the same quarter in the previous year.
Its net income has dropped by 1023.1% to $-2B since the same quarter in the previous year.
Finally, its free cash flow fell by 212.4% to $-554M since the same quarter in the previous year.
Based on the above factors, Solasia Pharma K.K gets an overall score of 2/5.